In honor of Black History Month, The Pharmacologist is highlighting the journey of Dionna Williams, PhD, Associate Professor at Emory University. Dr. Williams was one of two professors at Emory to recently receive the Presidential Early Career Award, the U.S. government’s highest honor for early-career scientists. She joined ASPET in 2022 and is a member of the Division for Drug Metabolism and Disposition.
Listen to ASPET President, Dr. Carol Beck, give updates on the recent science policy announcements, registration discounts for the ASPET 2025 Annual Meeting, the Washington Fellows program and more!
February 1, 2025, marked my 3-year anniversary as the Executive Officer of ASPET.
It has been both a privilege and a pleasure to serve in this role for the Society. While three years is a relatively small period to lead a scientific society that was founded in 1908, it’s also striking to me just how much has changed at ASPET during that time.
A Conversation with ASPET’s NYSPET Founding President
Saurabh Agarwal, PhD
Margarita Dubocovich Awarded with Nation’s Highest Honor in STEM Mentoring, ASPET Welcomes New Members
Honoring ASPET members who have passed.
The Latest Policy News Affecting Scientists: In response to the recent actions taken by the federal government affecting scientists and their research, ASPET leadership released the following statements to its members on January 29th and February 11th, respectively.
A showcase of early-career scientists—what drives them and why pharmacology is important to them.
The Publications Committee thanks the new editorial board members for 2025 and all ASPET board members for their service and dedication to the Society’s journals.
John D. Schuetz, PhD, is the inaugural Editor-in-Chief of ASPET Discovery, the newest Gold Open Access journal of the American Society for Pharmacology and Experimental Therapeutics. In partnership with Elsevier Publishing Company, ASPET Discovery, a peer-reviewed Open Access journal, will publish bi-monthly and include a range of article types including original research articles and minireviews that address all areas of pharmacology and experimental therapeutics. Dr. Schuetz will serve a three-year term that can be renewed for one additional three-year term.
